Table 3.
Multivariable Cox regression analysis of predictors of second-line ART failure of adult HIV positive patients at University of Gondar, Debretabor, and Felege Hiwot referral hospitals, September 2006 to April 2015
| Treatment failure |
Crude HR (95% CI) | Adjusted HR (95% CI) | ||
|---|---|---|---|---|
| Variable | Yes | No | ||
| Age (years) | ||||
| 15–29 | 17 | 61 | 1 | * |
| 30–39 | 26 | 141 | 0.7 (0.4 to 1.3) | 0.7 (0.4 to 1.4) |
| 40–49 | 14 | 68 | 0.8 (0.4 to 1.5) | 0.9 (0.4 to 1.8) |
| ≥50 | 10 | 19 | 1.8 (0.8 to 4.0) | 1.7 (0.8 to 3.9) |
| INH prophylaxis | ||||
| Yes | 3 | 30 | 2.3 (0.7 to 7.2) | 1.7 (0.5 to 5.7) |
| No | 64 | 259 | 1 | |
| Weight change (per 1 kg increase) | 0.9 (0.89 to 0.96) | 0.916 (0.88 to 0.95) | ||
| WHO clinical staging at switch | ||||
| I/II | 20 | 107 | 1 | |
| III | 29 | 143 | 0.8 (0.5 to 1.5) | 1.0 (0.6 to 1.8) |
| IV | 18 | 39 | 1.6 (0.8 to 3.0) | 2.1 (1.1 to 4.1) |
| CD4 cell count | ||||
| <100 cells/mm3 | 47 | 175 | 1.8 (1.0 to 2.9) | 2 (1.2 to 3.5) |
| ≥100 cells/mm3 | 20 | 114 | 1 | |
| NRTI‡ at first-line ART start | ||||
| Stavudine (d4T) | 29 | 104 | 1 | |
| Zidovudine (AZT) | 15 | 137 | 0.9 (0 0.5 to 1.5) | 0.9 (0.5 to 1.6) |
| Tenofovir (TDF) | 13 | 48 | 1.8 (0.9 to 3.6) | 1.9 (0.9 to 3.8) |
*Non-significant from the multivariable Cox regression.
ART, antiretroviral therapy; AZT, as lamivudine (3TC), zidovudine; INH,isoniazid; NRTI, nucleoside reverse transcriptase inhibitors.